Terns Pharmaceuticals, Inc.
Terns Pharmaceuticals, Inc. (TERN): 3 pipeline candidates · ~157 mo cash runway. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
156.6 months
D/E 0.02 · 0% dilution
Lead: Phase 2
3 candidates
N/A
0 buys · 11 sells (180d)
A transparent, data-derived signal for Terns Pharmaceuticals, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$6.1B
Cash
$524.7M
Quarterly Burn
$19.1M
Runway
156.6 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (3 candidates)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
323
Total value held
$7.24B
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 9,569,585 | $504.5M |
| vanguard capital management llc | 8,710,964 | $459.2M |
| morgan stanley | 6,449,140 | $340.0M |
| avoro capital advisors llc | 5,695,000 | $300.2M |
| holocene advisors, lp | 4,115,828 | $217.0M |
| balyasny asset management l.p. | 3,887,445 | $204.9M |
| citadel advisors llc | 3,747,310 | $197.6M |
| millennium management llc | 3,393,358 | $178.9M |
| hbk investments l p | 2,950,000 | $155.5M |
| janus henderson group plc | 2,940,114 | $155.0M |
Showing top 10 of 323 institutional holders of Terns Pharmaceuticals, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Terns Pharmaceuticals, Inc.'s pipeline?
Terns Pharmaceuticals, Inc. (TERN) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Terns Pharmaceuticals, Inc.'s lead drug candidate?
Terns Pharmaceuticals, Inc.'s most advanced tracked candidate is tern-501 (Phase 1) for Metabolic dysfunction-associated steatohepatitis (MASH) and/or obesity.
What is Terns Pharmaceuticals, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Terns Pharmaceuticals, Inc. has approximately 156.6 months of cash runway.
What is Terns Pharmaceuticals, Inc.'s market capitalization?
Terns Pharmaceuticals, Inc.'s market capitalization is approximately $6.1B.
Who is the CEO of Terns Pharmaceuticals, Inc.?
Ms. Amy L. Burroughs M.B.A. is the chief executive officer of Terns Pharmaceuticals, Inc. (TERN).
Get the full picture on Terns Pharmaceuticals, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.